Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Targiniq Patent Expiration

Targiniq is a drug owned by Purdue Pharma Lp. It is protected by 24 US drug patents filed from 2014 to 2018. Out of these, 5 drug patents are active and 19 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Mar 30, 2025. Details of Targiniq's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents protect the active ingredient(API) of the drug. Only drug patent owner can launch products that use this active ingredient until these patents expire.
US9522919 Oxycodone compositions
Mar, 2025

(4 months from now)

Active
US7674800 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(4 months from now)

Active
US7683072 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(4 months from now)

Active
US9073933 Oxycodone hydrochloride having less than 25 PPM 14-hydroxycodeinone
Mar, 2025

(4 months from now)

Active
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7674799 Oxycodone hydrochloride having less than 25 ppm 14-hydroxycodeinone
Mar, 2025

(4 months from now)

Active
US8846091 Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 7 months ago)

Expired
US8846090 Matrix for sustained, invariant and independent release of active compounds
Apr, 2023

(1 year, 7 months ago)

Expired
US9555000 Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 7 months ago)

Expired
US9907793 Pharmaceutical preparation containing oxycodone and naloxone
Apr, 2023

(1 year, 7 months ago)

Expired
US8969369 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9283216 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9161937 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9511066 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9056051 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9283221 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9168252 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9084729 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9345701 Abuse-resistant controlled-release opioid dosage form
May, 2022

(2 years ago)

Expired
US9474750 Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

Expired
US8822487 Opioid agonist/opioid antagonist/acetaminophen combinations
Dec, 2018

(5 years ago)

Expired
US6696066 Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

Expired
US9205082 Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

Expired
US6277384 Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

Expired
US8673355 Opioid agonist/antagonist combinations
Dec, 2018

(5 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Targiniq's patents.

Given below is the list of recent legal activities going on the following patents of Targiniq.

Activity Date Patent Number
Patent litigations
Expire Patent
Critical
 01 Jul, 2024 US9345701
Expire Patent
Critical
 22 Apr, 2024 US9283221
Expire Patent
Critical
 22 Apr, 2024 US9283216
Maintenance Fee Reminder Mailed
Critical
 15 Jan, 2024 US9345701
Expire Patent
Critical
 04 Dec, 2023 US9168252
Expire Patent
Critical
 27 Nov, 2023 US9161937
Maintenance Fee Reminder Mailed
Critical
 06 Nov, 2023 US9283216
Maintenance Fee Reminder Mailed
Critical
 06 Nov, 2023 US9283221
Expire Patent
Critical
 28 Aug, 2023 US9084729
Expire Patent
Critical
 24 Jul, 2023 US9056051


FDA has granted several exclusivities to Targiniq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Targiniq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Targiniq.

Exclusivity Information

Targiniq holds 1 exclusivities. All of its exclusivities have expired in 2017. Details of Targiniq's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Combination(NC) Jul 23, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Targiniq's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Targiniq's generic, the next section provides detailed information on ongoing and past EP oppositions related to Targiniq patents.

Targiniq's Oppositions Filed in EPO

Targiniq has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Sep 30, 2009, by Hexal Ag. This opposition was filed on patent number EP03720425A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11177518A Feb, 2018 Zentiva, k.s. Revoked
EP11177516A Feb, 2018 Zentiva, k.s. Revoked
EP11177516A Feb, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP11177518A Feb, 2018 Teva Pharmaceutical Industries Ltd Revoked
EP11177516A Feb, 2018 Intas Pharmaceuticals Ltd. Revoked
EP11177518A Feb, 2018 Intas Pharmaceuticals Ltd. Revoked
EP11177518A Jan, 2018 STADA Arzneimittel AG Revoked
EP11177516A Jan, 2018 STADA Arzneimittel AG Revoked
EP11177518A Nov, 2017 G. L. Pharma GmbH Revoked
EP11177516A Nov, 2017 G. L. Pharma GmbH Revoked
EP11177516A Nov, 2017 Ethypharm Revoked
EP11177518A Nov, 2017 Ethypharm Revoked
EP11177520A Aug, 2017 Ethypharm Revoked
EP11177520A Aug, 2017 Intas Pharmaceuticals Ltd. Revoked
EP11177520A Aug, 2017 Teva Pharmaceutical Industries Ltd Revoked
EP11177520A Aug, 2017 G. L. Pharma GmbH Revoked
EP11177516A Jul, 2017 Acino Pharma AG Revoked
EP11177518A Jul, 2017 Acino Pharma AG Revoked
EP11177520A Jun, 2017 STADA Arzneimittel AG Revoked
EP11177516A Jun, 2017 KRKA, d.d., Novo mesto Revoked
EP11177518A Jun, 2017 Krka, d.d., Novo mesto Revoked
EP11177516A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177518A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177520A May, 2017 Glenmark Pharmaceuticals Europe Ltd Revoked
EP11177518A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177518A May, 2017 Develco Pharma Schweiz AG Revoked
EP11177516A May, 2017 Develco Pharma Schweiz AG Revoked
EP11177516A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177520A May, 2017 Hexal AG / Sandoz International GmbH Revoked
EP11177520A Apr, 2017 Acino Supply AG Revoked
EP11177520A Apr, 2017 KRKA, d.d., Novo mesto Revoked
EP11177520A Mar, 2017 Develco Pharma Schweiz AG Revoked
EP11186168A Oct, 2016 James Poole Limited Opposition rejected
EP03720424A Mar, 2016 STADA Arzneimittel AG Revoked
EP03720424A Mar, 2016 KRKA, d.d., Novo mesto Revoked
EP03720424A Mar, 2016 FRKelly Revoked
EP03720424A Mar, 2016 Zentiva k.s. Revoked
EP03720424A Mar, 2016 Develco Pharma Schweiz AG Revoked
EP03720424A Mar, 2016 ETHYPHARM Revoked
EP03720424A Mar, 2016 G. L. Pharma GmbH Revoked
EP03720424A Mar, 2016 Hexal AG / Sandoz International GmbH Revoked
EP03720424A Feb, 2016 Teva Pharmaceutical Industries Ltd Revoked
EP03720424A Feb, 2016 Acino Pharma AG Revoked
EP03720424A Dec, 2015 Actavis Group PTC ehf Revoked
EP10011792A Oct, 2015 Setna, Rohan P. Granted and Under Opposition
EP10011792A Oct, 2015 Hoffmann Eitle Granted and Under Opposition
EP10011792A Oct, 2015 James Poole Limited Granted and Under Opposition
EP10011792A Oct, 2015 Acino Pharma AG Granted and Under Opposition
EP05730345A Dec, 2011 Actavis group PTC ehf Patent maintained as amended
EP05730345A Dec, 2011 Acino Pharma AG Patent maintained as amended
EP05730345A Dec, 2011 Elend, Almut Susanne Patent maintained as amended
EP03720425A Sep, 2009 Hexal AG Patent maintained as amended


US patents provide insights into the exclusivity only within the United States, but Targiniq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Targiniq's family patents as well as insights into ongoing legal events on those patents.

Targiniq's Family Patents

Targiniq has patent protection in a total of 44 countries. It's US patent count contributes only to 21.8% of its total global patent coverage. 6 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Targiniq.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Targiniq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Mar 30, 2025 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Targiniq Generics:

There are no approved generic versions for Targiniq as of now.

Alternative Brands for Targiniq

Targiniq which is used for managing severe chronic pain when alternative treatment options are inadequate, requiring daily, around-the-clock, long-term opioid treatment., has several other brand drugs in the same treatment category . Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name Treatment Area
Bdsi
Belbuca Used for managing severe, long-term pain when other treatments are insufficient, through transmucosal delivery of buprenorphine.
Collegium Pharm Inc
Xtampza Er Used for managing severe, chronic pain when other treatment options are insufficient.
Purdue Pharma Lp
Butrans Used for chronic pain management when other treatment options are inadequate, requiring long-term around-the-clock opioid therapy.
Oxycontin used for managing moderate to severe pain that requires long-term opioid treatment when other options are inadequate.
Hysingla Er used for managing severe chronic pain when other treatment options are insufficient.
Zyla
Arymo Er Used for chronic pain management when other treatment options are ineffective.





About Targiniq

Targiniq is a drug owned by Purdue Pharma Lp. It is used for managing severe chronic pain when alternative treatment options are inadequate, requiring daily, around-the-clock, long-term opioid treatment. Targiniq uses Naloxone Hydrochloride; Oxycodone Hydrochloride as an active ingredient. Targiniq was launched by Purdue Pharma Lp in 2014.

Approval Date:

Targiniq was approved by FDA for market use on 23 July, 2014.

Active Ingredient:

Targiniq uses Naloxone Hydrochloride; Oxycodone Hydrochloride as the active ingredient. Check out other Drugs and Companies using Naloxone Hydrochloride; Oxycodone Hydrochloride ingredient

Treatment:

Targiniq is used for managing severe chronic pain when alternative treatment options are inadequate, requiring daily, around-the-clock, long-term opioid treatment.

Dosage:

Targiniq is available in tablet, extended release form for oral use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
20MG;40MG TABLET, EXTENDED RELEASE Discontinued ORAL
10MG;20MG TABLET, EXTENDED RELEASE Discontinued ORAL
5MG;10MG TABLET, EXTENDED RELEASE Discontinued ORAL